Lonsurf (trifluridine / tipiracil)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Lonsurf (trifluridine / tipiracil)

How to buy Lonsurf: You can order Lonsurf (trifluridine / tipiracil) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSoclalMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Taiho Pharmaceuticals
Disease Colorectal Cancer
Indication Advanced (metastatic) colorectal cancer
Mode of Action Cytotoxic agent (chemotherapy)
Approval Status EMA approved (EU); FDA approved (USA); PMDA approved (JAP)
CAS Number 183204-74-2
HS Code 29335995
Strength 15 mg / 6.14 mg, 20 mg / 8.19 mg

Who is trifluridine/tipiracil for?

Trifluridine/tipiracil is an oral medication intended to treat patients with advanced (metastatic) colorectal cancer who have been previously treated with chemotherapy and biological therapy [1][2].

Recommended dose

Complete information about trifluridine/tipiracil dosage and administration can be found here [3][4][6].
  • The recommended therapy consists of 35 mg/m2/dose orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle.
  • Take trifluridine/tipiracil within 1 hour after completion of morning and evening meals.
Consult your treating doctor for personalised dosing.
What is trifluridine/tipiracil and how does it work?
Trifluridine/tipiracil is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells). It contains two active substances: trifluridine and tipiracil. In the body, trifluridine is converted into an active form that is incorporated directly into DNA, the genetic material of cells. As a result, trifluridine interferes with DNA function and prevents the cells from dividing and multiplying. The conversion of trifluridine into its active form occurs more readily in cancer cells than in normal cells, leading to higher levels of the active form of the medicine and a longer duration of action in cancer cells. This results in the growth of cancer cells being reduced, while normal cells are only slightly affected. Tipiracil increases the level of trifluridine in the blood by slowing its breakdown. This, therefore, boosts trifluridine’s effect [2].

What is trifluridine/tipiracil's approval status?

Trifluridine/tipiracil was approved by
  • PMDA (JAP) on February 3, 2016
  • FDA (USA) on September 22, 2015
  • EMA (EU) on April 25, 2016
  • TGA (AUS) on May 23, 2017
for advanced (metastatic) colorectal cancer who have been previously treated with, or who cannot be given, other available treatments [1][2][5][6].
The efficacy and safety of Lonsurf were evaluated in an international, randomized, double-blind study involving 800 patients with previously treated metastatic colorectal cancer. The EMA, FDA, and TGA approvals were based on this study. The Japanese approval was based on previous studies which had to be confirmed by the results of the above-mentioned international study.
Study participants received Lonsurf plus best supportive care, or placebo plus best supportive care until their disease worsened or side effects became intolerable. The primary endpoint of the study was overall survival and the secondary endpoint was progression-free survival. Patients treated with Lonsurf lived an average of 7.1 months compared to 5.3 months for those treated with placebo [1][2]. On average, the time to disease progression was 2 months for patients on Lonsurf compared to 1.7 months for patients receiving placebo [1].
The most common side effects of treatment with Lonsurf are anemia, a decrease in infection-fighting white blood cells (neutropenia) or blood platelets (thrombocytopenia), physical weakness, extreme tiredness and lack of energy (fatigue), nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and fever [3][4].
It is recommended that healthcare providers obtain complete blood counts prior to starting each treatment cycle of Lonsurf and monitor patients throughout treatment, as trifluridine/tipiracil may cause a severe decrease in blood cell and platelet production (myelosuppression) [1][4].
[1] FDA News Release: FDA approves new oral medication to treat patients with advanced colorectal cancer. 22/09/2015.
[2] EMA. Human Medicines: Lonsurf (trifluridine / tipiracil), 12/05/2016 (last update: 31/05/2017), cited on 16/03/2017.
[3] Summary of Product Characteristics [FDA]: Lonsurf (trifluridine / tipiracil), Taiho Oncology Inc., Sep. 2015.
[4] Summary of Product Characteristics [EMA]: Lonsurf (trifluridine / tipiracil), Les Laboratoires Servier, Sep. 2015.
[5] PMDA. Report on deliberation results. 07/02/2014.
[6] Summary of Product Characteristics [TGA]: Lonsurf (trifluridine / tipiracil), Servier Laboratories (Aust.) Pty Ltd,May 2017.

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Our service uses cookies.